Stiris Research Announces First Site Initiated in COVID-19 Rescue Study

London, ON — November 16, 2021 —

Stiris Research Inc. (“Stiris”), an entrepreneurial clinical trial management company focused on the management of Phase I-IIIB trials, today announced that the first site has been successfully initiated in an efficacy trial of an investigational treatment in COVID-19.

“We are extremely pleased to have the opportunity to work on a novel therapy people who are at higher risk of developing serious illness due to COVID-19. After a year and a half of living through the pandemic and working in the vaccine space, it is interesting and exciting to have the chance to now work on a treatment option in this therapeutic area, said, Amanda Carrera, Vice President.

Coronavirus disease (COVID-19) is an infectious disease caused by SARS-CoV-2 virus. Researchers know that the virus is spread from an infected person when respiratory droplets containing the virus particles are released into the air when the person breathes, coughs, sneezes, sings and speaks.

About Stiris Research

Stiris Research is an entrepreneurial Clinical Trial Management company specializing in conducting complex Phase I through IIIB trials for North American biotechnology and biopharmaceutical companies, with a focus on Oncology, CNS and Neurology. Stiris Research was formed as a result of listening to the stakeholders engaged in clinical trials, identifying their unmet needs, and developing a unique, value-based approach to address those needs.

For more information, please contact:

Marketing – Stiris Research Inc.